keyword
MENU ▼
Read by QxMD icon Read
search

SNRI

keyword
https://www.readbyqxmd.com/read/29763613/neuroprotective-effect-of-duloxetine-in-a-mouse-model-of-diabetic-neuropathy-role-of-glia-suppressing-mechanisms
#1
Mona K Tawfik, Seham A Helmy, Dahlia I Badran, Sawsan A Zaitone
AIMS: Painful diabetic neuropathy (PDN) is one of the most frequent complications of diabetes and the current therapies have limited efficacy. This study aimed to study the neuroprotective effect of duloxetine, a serotonin noradrenaline reuptake inhibitor (SNRI), in a mouse model of diabetic neuropathy. MAIN METHODS: Nine weeks after developing of PDN, mice were treated with either saline or duloxetine (15 or 30 mg/kg) for four weeks. The effect of duloxetine was assessed in terms of pain responses, histopathology of sciatic nerve and spinal cord, sciatic nerve growth factor (NGF) gene expression and on the spinal expression of astrocytes (glial fibrillary acidic protein, GFAP) and microglia (CD11 b)...
May 12, 2018: Life Sciences
https://www.readbyqxmd.com/read/29760569/concomitant-use-of-opioid-medications-with-triptans-or-serotonergic-antidepressants-in-us-office-based-physician-visits
#2
Kyle C Molina, Kathleen A Fairman, David A Sclar
Background: Opioids are not recommended for routine treatment of migraine because their benefits are outweighed by risks of medication overuse headache and abuse/dependence. A March 2016 US Food and Drug Administration (FDA) safety communication warned of the risk of serotonin syndrome from using opioids concomitantly with 5-hydroxytryptamine receptor agonists (triptans) or serotonergic antidepressants: selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs)...
2018: Drug, Healthcare and Patient Safety
https://www.readbyqxmd.com/read/29758951/ssri-and-snri-withdrawal-symptoms-reported-on-an-internet-forum
#3
Tom Stockmann, Dolapo Odegbaro, Sami Timimi, Joanna Moncrieff
BACKGROUND: Antidepressant withdrawal symptoms are well-recognised, but their potential duration remains uncertain. OBJECTIVE: We aimed to describe the characteristics of withdrawal associated with two popular classes of antidepressants, including duration. METHODS: We analysed the content of a sample of posts on an antidepressant withdrawal website. We compared the characteristics of withdrawal associated with SSRIs and SNRIs, including time of onset, duration and nature of symptoms...
May 9, 2018: International Journal of Risk & Safety in Medicine
https://www.readbyqxmd.com/read/29738425/a-pilot-open-label-8-week-study-evaluating-desvenlafaxine-for-treatment-of-major-depression-in-methadone-maintained-individuals-with-opioid-use-disorder
#4
Cynthia El Hage, Maykel F Ghabrash, Simon Dubreucq, Suzanne Brissette, François Lespérance, Paul Lespérance, Clairélaine Ouellet-Plamondon, Julie Bruneau, Didier Jutras-Aswad
Depression is one of the most prevalent psychiatric disorders among opioid-dependent individuals. Clinical trials testing selective serotonin reuptake inhibitors among depressed patients on methadone maintenance therapy (MMT) failed to show efficacy, whereas those on tricyclic antidepressants produced mixed results with potential for cardiotoxicity. Desvenlafaxine (DESV) is a SNRI with minimal cardiotoxicity and drug interactions. This study sought to assess feasibility and tolerability of using DESV in depressed patients on MMT...
May 7, 2018: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29736080/galactorrhea-with-antidepressants-a-case-series
#5
Navratan Suthar, Vrinda Pareek, Naresh Nebhinani, Deep Kunwar Suman
Galactorrhoea is a rare but distressing, and often embarrassing adverse effects of selective serotonin reuptake inhibitors (SSRIs) treatment. Here we report three cases that developed galactorrhoea with combination of SSRIs or combination of SSRI and SNRI/TCA and also review the literature of galactorrhoea with SSRIs.
January 2018: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/29685287/the-circulating-levels-of-cd4-t-helper-cells-are-higher-in-bipolar-disorder-as-compared-to-major-depressive-disorder
#6
Karlijn Becking, Bartholomeus C M Haarman, Laura Grosse, Willem A Nolen, Stephan Claes, Volker Arolt, Robert A Schoevers, Hemmo A Drexhage
INTRODUCTION: Clinical differentiation between bipolar disorder (BD) and major depressive disorder (MDD) is difficult. Research has therefore focused on discriminatory biological markers. Previous studies in MDD reported T cell deficits, while the limited studies in BD reported T cell activation. Studies directly comparing circulating numbers of T cells and T cell subsets between BD and MDD are lacking. The studies in the MOODINFLAME consortium make such a comparison possible. METHODS: The number of circulating leukocyte populations (lymphocytes, monocytes, NK cells, B cells, T cells, CD3+CD8+ T cytotoxic cells, CD3+CD4+ T helper cells, Th1, Th2, Th17 and T regulatory cells) was determined using FACS technology in a cohort of 83 euthymic BD patients, 8 BD patients with a current mood episode and 165 healthy controls (HC)...
June 15, 2018: Journal of Neuroimmunology
https://www.readbyqxmd.com/read/29674777/-la-diagnostic-clinical-interview-for-drug-withdrawal-1-did-w1-new-symptoms-of-selective-serotonin-reuptake-inhibitors-ssri-or-serotonin-norepinephrine-reuptake-inhibitors-snri-affidabilit%C3%A3-fra-valutatori
#7
Fiammetta Cosci, Guy Chouinard, Virginie-Anne Chouinard, Giovanni Andrea Fava
RIASSUNTO. Scopo. Dopo la riduzione della dose o la sospensione di Selective Serotonin Reuptake Inhibitors (SSRI) o di Serotonin Norepinephrine Reuptake Inhibitors (SNRI) si possono verificare molti fenomeni clinici. Nel 2015, è stata delineata una nuova classificazione delle sindromi d'astinenza da SSRI/SNRI (cioè, nuovi sintomi, rimbalzo, disturbi persistenti post-astinenza) sulla base della letteratura e delle osservazioni cliniche. Un'intervista clinica semistrutturata, la Diagnostic clinical Interview for Drug Withdrawal 1 - New Symptoms of SSRI and SNRI (DID-W1), è stata sviluppata allo scopo di identificare e differenziare queste sindromi...
March 2018: Rivista di Psichiatria
https://www.readbyqxmd.com/read/29620793/antidepressants-versus-placebo-for-panic-disorder-in-adults
#8
REVIEW
Irene Bighelli, Mariasole Castellazzi, Andrea Cipriani, Francesca Girlanda, Giuseppe Guaiana, Markus Koesters, Giulia Turrini, Toshi A Furukawa, Corrado Barbui
BACKGROUND: Panic disorder is characterised by repeated, unexpected panic attacks, which represent a discrete period of fear or anxiety that has a rapid onset, reaches a peak within 10 minutes, and in which at least four of 13 characteristic symptoms are experienced, including racing heart, chest pain, sweating, shaking, dizziness, flushing, stomach churning, faintness and breathlessness. It is common in the general population with a lifetime prevalence of 1% to 4%. The treatment of panic disorder includes psychological and pharmacological interventions...
April 5, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29554497/efficacy-and-tolerability-of-vortioxetine-versus-agomelatine-categorized-by-previous-treatment-in-patients-with-major-depressive-disorder-switched-after-an-inadequate-response
#9
George I Papakostas, Rebecca Z Nielsen, Marianne Dragheim, Brigitte Tonnoir
This study aimed to evaluate if efficacy and tolerability of switching to vortioxetine is independent of previous SSRI or SNRI treatment in patients who had been inadequately treated for their current major depressive episode. Patients from a double-blind, 12-week comparator study were randomized (1:1) to vortioxetine (10-20 mg/day) or agomelatine (25-50 mg/day). The pre-defined primary efficacy endpoint was change from baseline to week 8 in MADRS total score analyzed by MMRM. An ANCOVA-LOCF was conducted as a sensitivity analysis...
June 2018: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/29544744/the-impact-of-depression-medications-on-oral-antidiabetic-drug-adherence-in-patients-with-diabetes-and-depression
#10
Shan Xing, Gregory S Calip, Alex D Leow, Shiyun Kim, Glen T Schumock, Daniel R Touchette, Todd A Lee
AIMS: To compare adherence and persistence to oral antidiabetic drugs (OAD) between patients who are new users of second generation antipsychotics (SGA) versus new users of other depression therapies in adults with type 2 diabetes mellitus (T2DM) and major depressive disorder (MDD). METHODS: Adults 18-64 years with previously-treated T2DM and MDD (past OAD and SSRI/SNRI use) who are new users of SGA or non-SGA therapies (bupropion, lithium, mirtazapine, thyroid hormone, tricyclic antidepressant) were identified in the 2009-2015 MarketScan® Commercial Claims and Encounters database...
December 27, 2017: Journal of Diabetes and its Complications
https://www.readbyqxmd.com/read/29533962/antidepressant-use-by-class-association-with-major-adverse-cardiac-events-in-patients-with-coronary-artery-disease
#11
Sherry L Grace, Jose R Medina-Inojosa, Randal J Thomas, Heather Krause, Kristin S Vickers-Douglas, Brian A Palmer, Francisco Lopez-Jimenez
BACKGROUND: To assess use of antidepressants by class in relation to cardiology practice recommendations, and the association of antidepressant use with the occurrence of major adverse cardiovascular events (MACE) including death. METHODS: This is a historical cohort study of all patients who completed cardiac rehabilitation (CR) between 2002 and 2012 in a major CR center. Participants completed the Patient Health Questionnaire (PHQ-9) at the start and end of the program...
2018: Psychotherapy and Psychosomatics
https://www.readbyqxmd.com/read/29482205/association-of-coprescription-of-triptan-antimigraine-drugs-and-selective-serotonin-reuptake-inhibitor-or-selective-norepinephrine-reuptake-inhibitor-antidepressants-with-serotonin-syndrome
#12
Yulia Orlova, Paul Rizzoli, Elizabeth Loder
Importance: In 2006, the US Food and Drug Administration (FDA) issued an advisory warning on the risk of serotonin syndrome with concomitant use of triptans and selective serotonin reuptake inhibitor (SSRI) or selective norepinephrine reuptake inhibitor (SNRI) antidepressants, but the true risk of serotonin syndrome in these patients remains unknown. Objective: To assess the risk of serotonin syndrome with concomitant use of triptans and SSRI or SNRI antidepressants...
February 26, 2018: JAMA Neurology
https://www.readbyqxmd.com/read/29475215/korean-guidelines-for-the-pharmacological-treatment-of-social-anxiety-disorder-initial-treatment-strategies
#13
Hyungkun Yoon, Dong Jae Oh, Ho-Suk Suh, Kyoung-Uk Lee, Se-Won Lim, Jun-Yeob Lee, Jong-Chul Yang, Jae-Hon Lee, Juwon Ha, Bun-Hee Lee, Seung-Gul Kang, Ho-Kyoung Yoon, Jihyun Moon, Seung-Min Bae, Youngdo Kwon, Hyun-Chung Kim, Kang Seob Oh
OBJECTIVE: The aim of the present study was to provide clinical consensus and evidence regarding initial treatment strategies for the pharmacological treatment of social anxiety disorder (SAD) in Korea. METHODS: We prepared a questionnaire to derive a consensus from clinicians regarding their preference for the pharmacological treatment of SAD in Korea. Data regarding medication regimens and psychotropic drugs used during initial treatment, the doses used, and the pharmacological treatment duration were obtained...
February 2018: Psychiatry Investigation
https://www.readbyqxmd.com/read/29459641/therapeutic-effects-of-diclofenac-pregabalin-and-duloxetine-on-disuse-induced-chronic-musculoskeletal-pain-in-rats
#14
Yusuke Ohmichi, Mika Ohmichi, Nobuhito Murai, Masaya Yasui, Nobuaki Takeshita, Hidehiro Oshibuchi, Munekazu Naito, Takashi Nakano, Jun Sato
The aim of this study was to clarify the mechanism of disuse-induced muscle hyperalgesia through the evaluation of the pharmacological behaviour of muscle hyperalgesia profiles in chronic post-cast pain (CPCP) rats with acute and chronic-phase mirror-image muscle hyperalgesia treated with diclofenac (NSAID), pregabalin (an inhibitor of Ca2+ channel α2δ), and duloxetine (SNRI). After 2 weeks of cast immobilization, the peak cross-sectional area and muscle wet weight of the ipsilateral soleus and gastrocnemius muscles decreased more significantly in CPCP rats than in untreated rats...
February 19, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29386481/chronopharmacological-analysis-of-antidepressant-activity-of-a-dual-action-serotonin-noradrenaline-reuptake-inhibitor-snri-milnacipran-in-rats
#15
Hiroshi Kawai, Megumi Machida, Takuya Ishibashi, Naomi Kudo, Yoichi Kawashima, Atsushi Mitsumoto
Biological rhythms are thought to be related to the pathogenesis and therapy of various diseases including depression. Here we investigated the influence of circadian rhythms on the antidepressant activity of the dual-action serotonin-noradrenaline reuptake inhibitor (SNRI) milnacipran. Rats administered milnacipran in the morning (8:00 a.m.; zeitgeber time [ZT]1) or in the evening (8:00 p.m.; ZT13) were analyzed in a forced swim test (FST). At ZT1, the rats' immobility was reduced and the swimming was increased, whereas at ZT13, their climbing was increased...
2018: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/29380718/antidepressant-switching-patterns-in-the-elderly
#16
Svetla Gadzhanova, Elizabeth E Roughead, Lisa G Pont
BACKGROUND: Switching between antidepressants is complex due to potential adverse outcomes such as serotonin syndrome and antidepressant discontinuation syndrome, yet switching is often required due to non-response to initial treatment. This study aimed to examine the patterns and extent of antidepressant switching in a cohort of older adults in long-term residential care. METHODS: A cohort study of medication supply data from 6011 aged care residents in 60 long-term care facilities was conducted...
January 30, 2018: International Psychogeriatrics
https://www.readbyqxmd.com/read/29331709/what-do-the-genetic-association-data-say-about-the-high-risk-of-suicide-in-people-with-depression-a-novel-network-based-approach-to-find-common-molecular-basis-for-depression-and-suicidal-behavior-and-related-therapeutic-targets
#17
Ali Bozorgmehr, Fatemeh Alizadeh, Sattar Norouzi Ofogh, Mohammad Reza Abdollahzadeh Hamzekalayi, Sara Herati, Atefeh Moradkhani, Ali Shahbazi, Mohammad Ghadirivasfi
BACKGROUND: Available sources indicate that the risk of suicide in people with major depression is higher than other psychiatric disorders. Although it seems that these two conditions may have a shared cause in some cases, no studies have been conducted to identify a common basis for them. METHODS: In this study, following an extensive review of literature, we found almost all the genes that are involved in major depression and suicidal behavior, and we isolated genes shared between the two conditions...
March 15, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29300091/what-contributes-to-serotonin-norepinephrine-reuptake-inhibitors-dual-targeting-mechanism-the-key-role-of-transmembrane-domain-6-in-human-serotonin-and-norepinephrine-transporters-revealed-by-molecular-dynamics-simulation
#18
Weiwei Xue, Fengyuan Yang, Panpan Wang, Guoxun Zheng, Yuzong Chen, Xiaojun Yao, Feng Zhu
Dual inhibition of serotonin and norepinephrine transporters (hSERT and hNET) gives greatly improved efficacy and tolerability for treating major depressive disorder (MDD) compared with selective reuptake inhibitors. Pioneer studies provided valuable information on structure, function, and pharmacology of drugs targeting both hSERT and hNET (serotonin-norepinephrine reuptake inhibitors, SNRIs), and the differential binding mechanism between SNRIs and selective inhibitors of 5-HT (SSRIs) or NE (sNRIs) to their corresponding targets was expected to be able to facilitate the discovery of a privileged drug-like scaffold with improved efficacy...
January 24, 2018: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/29278206/a-systematic-review-of-evidence-based-treatment-strategies-for-obsessive-compulsive-disorder-resistant-to-first-line-pharmacotherapy
#19
Umberto Albert, Donatella Marazziti, Gabriele Di Salvo, Francesca Solia, Gianluca Rosso, Giuseppe Maina
BACKGROUND: Serotonin reuptake inhibitors (SRIs) and cognitive-behavioral psychotherapy (CBT) are first-line treatments for obsessive-compulsive disorder (OCD). However, a significant proportion of patients do not respond satisfactorily to first-choice treatments. Several options have been investigated for the management of resistant patients. OBJECTIVE: The aim of the present paper is to systematically review the available literature concerning the strategies for the treatment of resistant adult patients with OCD...
December 22, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29274375/meta-analysis-risk-of-dry-mouth-with-second-generation-antidepressants
#20
Kiley Cappetta, Chad Beyer, Jessica A Johnson, Michael H Bloch
OBJECTIVE: The goal of this meta-analysis was to quantify the risk of dry mouth associated with commonly prescribed antidepressant agents and examine the potential implications of medication class, dose, and pharmacodynamics and dose on risk of treatment-induced dry mouth. DATA SOURCES AND STUDY SELECTION: A PubMed search was conducted to identify double-blind, randomized, placebo-controlled trials examining the efficacy and tolerability of second generation antidepressant medications for adults with depressive disorders, anxiety disorders, and OCD...
December 20, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
keyword
keyword
32930
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"